nodgoРоссийский журнал детской гематологии и онкологии (РЖДГиО)Russian Journal of Pediatric Hematology and Oncology2311-12672413-5496LTD “Graphica”10.21682/2311-1267-2020-7-2-115-9nodgo-610Research ArticleКЛИНИЧЕСКИЕ НАБЛЮДЕНИЯCLINICAL CASESВторичная Т-лимфобластная лимфома у ребенка после завершения противоопухолевой терапии по поводу нейробластомы: клинический случайSecondary T-cell lymphoblastic lymphoma in a child after anticancer therapy for neuroblastoma: clinical casehttps://orcid.org/0000-0001-9753-9536ТошинаЮ. К.ToshinaYu. K.

Юлия Константиновна Тошина, врач-детский онколог отделения химиотерапии онкогематологических заболеваний и трансплантации костного мозга для детей

Россия, 197341, Санкт-Петербург, ул. Аккуратова, 2

Yu.K. Toshina, Pediatric Oncologist, Department of Chemotherapy for Hematologic Diseases and Bone Marrow Transplantation for Children

2 Akkuratova St., S.-Petersburg, 197341, Russia

yuliyatoshina@ya.ruhttps://orcid.org/0000-0002-2003-0982ДиникинаЮ. В.DinikinaYu. V.

к.м.н., заведующая отделением химиотерапии онкогематологических заболеваний и трансплантации костного мозга для детей; доцент кафедры онкологии, детской онкологии и лучевой терапии

Россия, 197341, Санкт-Петербург, ул. Аккуратова, 2

Россия, 194100, Санкт-Петербург, ул. Литовская, 2

Cand. of Sci. (Med.), Head of the Department of Chemotherapy for Hematologic Diseases and Bone Marrow Transplantation for Children; Associate Professor Department of Oncology, Pediatric Oncology and Radiotherapy

2 Akkuratova St., S.-Petersburg, 197341, Russia

2 Litovskaya St., S.-Petersburg, 194100, Russia

dinikinayulia@mail.ruhttps://orcid.org/0000-0002-2764-5904ЕгоровА. С.EgorovA. S.

к.м.н., врач-гематолог отделения химиотерапии онкогематологических заболеваний и трансплантации костного мозга для детей

Россия, 197341, Санкт-Петербург, ул. Аккуратова, 2

Cand. of Sci. (Med.), Hematologist Department of Chemotherapy for Hematologic Diseases and Bone Marrow Transplantation for Children

2 Akkuratova St., S.-Petersburg, 197341, Russia

egorov.doc@gmail.comhttps://orcid.org/0000-0002-5293-9568СмирноваА. Ю.SmirnovaA. Yu.

врач-детский онколог отделения химиотерапии онкогематологических заболеваний и трансплантации костного мозга для детей

Россия, 197341, Санкт-Петербург, ул. Аккуратова, 2

Pediatric Oncologist Department of Chemotherapy for Hematologic Diseases and Bone Marrow Transplantation for Children

2 Akkuratova St., S.-Petersburg, 197341, Russia

misha12_09@mail.ruhttps://orcid.org/0000-0002-7471-7181БелогуроваМ. Б.BelogurovaM. B.

д.м.н., профессор, ведущий научный сотрудник НИИ онкологии и гематологии, заведующая кафедрой онкологии, детской онкологии и лучевой терапии

Россия, 197341, Санкт-Петербург, ул. Аккуратова, 2

Россия, 194100, Санкт-Петербург, ул. Литовская, 2

Leading Scientific Collaborator of Research Institute of Oncology and Hematology; Dr. of Sci. (Med.), Professor, Head of the Department of Oncology, Pediatric Oncology and Radiotherapy

2 Akkuratova St., S.-Petersburg, 197341, Russia

2 Litovskaya St., S.-Petersburg, 194100, Russia

deton.hospital31@inbox.ruФГБУ «Национальный медицинский исследовательский центр имени В.А. Алмазова» Минздрава РоссииРоссияAlmazov National Medical Research Centre, Ministry of Health of RussiaRussian FederationФГБУ «Национальный медицинский исследовательский центр имени В.А. Алмазова» Минздрава России; ФГБОУ ВО «Санкт-Петербургский государственный педиатрический медицинский университет» Минздрава РоссииРоссияAlmazov National Medical Research Centre, Ministry of Health of Russia; Saint-Petersburg State Pediatric Medical University, Ministry of Health of RussiaRussian Federation20200407202072115119Copyright © Тошина Ю.К., Диникина Ю.В., Егоров А.С., Смирнова А.Ю., Белогурова М.Б., 20202020Тошина Ю.К., Диникина Ю.В., Егоров А.С., Смирнова А.Ю., Белогурова М.Б.Toshina Y.K., Dinikina Y.V., Egorov A.S., Smirnova A.Y., Belogurova M.B.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nodgo.org/jour/article/view/610

Нейробластома (НБ) является наиболее частой экстракраниальной солидной опухолью у детей раннего возраста, при этом отличается наибольшей гетерогенностью клинического течения. Использование интенсивных мультимодальных программ противоопухолевого лечения позволяет увеличивать выживаемость пациентов, при этом все более актуальными становятся вопросы отдаленных эффектов противоопухолевой терапии. Одним из них является риск развития вторичных злокачественных опухолей (ВО). В статье представлено описание клинического случая развития Т-лимфобластной лимфомы у ребенка в возрасте 2 лет 5 месяцев, получавшего комбинированную противоопухолевую терапию по поводу НБ промежуточной группы риска в возрасте до 1 года. Мы изучили данные литературы по частоте ВО у детей после лечения НБ за период с 1948 по 2018 г. и провели анализ факторов риска.

Neuroblastoma (NB) is the most common extra-cranial solid tumor in infants with the most heterogeneous clinical course to compare with other malignant diseases. Due to intensive multimodal anticancer treatment there are an increased number of survivors and issues related to long-term effects are becoming increasingly important. One of them is the risk of secondary malignant neoplasms. This article represents a clinical case of T-cell lymphoblastic leukemia in a child aged 2 years and 5 months who received combined antitumor therapy for NB with an intermediate risk group under the age of one year. We observed literature data to investigate the incidence of second malignant neoplasms in patients with NB for the period from 1948 to 2018 and analyzed risk factors.

детидетская онкологиянейробластомаТ-клеточная лимфомавторичные опухолипротивоопухолевая терапияchildrenpediatric oncologyneuroblastomaT-cell lymphomasecondary neoplasmsanticancer therapyReferencesFederico S.M., Allewelt H.B., Spunt S.L., Hudson M.M., Wu J., Billups C.A., Jenkins J., Santana V.M., Furman W.L., McGregor L.M. Subsequent malignant neoplasms in pediatric patients initially diagnosed with neuroblastoma. J Pediatr Hematol Oncol 2015;37(1):e6–12. doi: 10.1097/mph.0000000000000148.Federico S.M., Allewelt H.B., Spunt S.L., Hudson M.M., Wu J., Billups C.A., Jenkins J., Santana V.M., Furman W.L., McGregor L.M. Subsequent malignant neoplasms in pediatric patients initially diagnosed with neuroblastoma. J Pediatr Hematol Oncol 2015;37(1):e6–12. doi: 10.1097/mph.0000000000000148.Laverdière C., Liu Q., Yasui Y., Nathan P.C., Gurney J.G., Stovall M., Diller L.R., Cheung N.K., Wolden S., Robison L.L., Sklar C.A. Longterm outcomes in survivors of neuroblastoma: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst 2009;101(16):1131–40. doi: 10.1093/jnci/djp230.Laverdière C., Liu Q., Yasui Y., Nathan P.C., Gurney J.G., Stovall M., Diller L.R., Cheung N.K., Wolden S., Robison L.L., Sklar C.A. Longterm outcomes in survivors of neuroblastoma: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst 2009;101(16):1131–40. doi: 10.1093/jnci/djp230.Applebaum M.A., Henderson T.O., Lee S.M., Pinto N., Volchenboum S.L., Cohn S.L. Second malignancies in patients with neuroblastoma: the effects of risk-based therapy. Pediatr Blood Cancer 2015;62(1):128–33. doi: 10.1002/pbc.25249.Applebaum M.A., Henderson T.O., Lee S.M., Pinto N., Volchenboum S.L., Cohn S.L. Second malignancies in patients with neuroblastoma: the effects of risk-based therapy. Pediatr Blood Cancer 2015;62(1):128–33. doi: 10.1002/pbc.25249.Applebaum M.A., Vaksman Z., Lee S.M., Hungate E.A., Henderson T.O., Londone W.B., Pinto N., Volchenboum S.L., Park J.R., Naranjo A., Hero B., Pearson A.D., Stranger B.E., Cohn S.L., Diskin S.J. Neuroblastoma survivors are at increased risk for second malignancies: a report from the International Neuroblastoma Risk Group Project. Eur J Cancer 2017;72:177–85. doi: 10.1016/j.ejca.2016.11.022.Applebaum M.A., Vaksman Z., Lee S.M., Hungate E.A., Henderson T.O., Londone W.B., Pinto N., Volchenboum S.L., Park J.R., Naranjo A., Hero B., Pearson A.D., Stranger B.E., Cohn S.L., Diskin S.J. Neuroblastoma survivors are at increased risk for second malignancies: a report from the International Neuroblastoma Risk Group Project. Eur J Cancer 2017;72:177–85. doi: 10.1016/j.ejca.2016.11.022.Rubino C., Adjadj E., Gurerin S., Guibout C., Shamsadin A., Dondon M.-G., Valteau-Couanet D., Hartmann O., Hawkins M., de Vathaire F. Long-term risk of second malignant neoplasm after neuroblastoma in childhood: role of treatment. Int J Cancer 2003;107:791–6. doi: 10.1002/ijc.11455.Rubino C., Adjadj E., Gurerin S., Guibout C., Shamsadin A., Dondon M.-G., Valteau-Couanet D., Hartmann O., Hawkins M., de Vathaire F. Long-term risk of second malignant neoplasm after neuroblastoma in childhood: role of treatment. Int J Cancer 2003;107:791–6. doi: 10.1002/ijc.11455.Kushner B.H., Kramer K., Modak S., Qin L.X., Yataghena K., Jhanwar S.C., Cheung N.K. Reduced risk of secondary leukemia with fewer cycles of dose-intensive induction chemotherapy in patients with neuroblastoma. Pediatr Blood Cancer 2009;53:17–22. doi: 10.1002/pbc.21931.Kushner B.H., Kramer K., Modak S., Qin L.X., Yataghena K., Jhanwar S.C., Cheung N.K. Reduced risk of secondary leukemia with fewer cycles of dose-intensive induction chemotherapy in patients with neuroblastoma. Pediatr Blood Cancer 2009;53:17–22. doi: 10.1002/pbc.21931.Martin A., Schneiderman J., Helenowski I.B., Morgan E., Dilley K., Danner-Koptik K., Hatahet M., Shimada H., Cohn S.L., Kletzel M., Hijiya N. Secondary malignant neoplasms after high-dose chemotherapy and autologous stem cell rescue for high-risk neuroblastoma. Pediatr Blood Cancer 2014;61(8):1350–6. doi: 10.1002/pbc.25033.Martin A., Schneiderman J., Helenowski I.B., Morgan E., Dilley K., Danner-Koptik K., Hatahet M., Shimada H., Cohn S.L., Kletzel M., Hijiya N. Secondary malignant neoplasms after high-dose chemotherapy and autologous stem cell rescue for high-risk neuroblastoma. Pediatr Blood Cancer 2014;61(8):1350–6. doi: 10.1002/pbc.25033.Garaventa A., Gambini C., Villavecchia G., Cataldo A., Bertolazzi L., Pizzitola M.R., de Bernardi B., Haupt R. Second malignancies in children with neuroblastoma after combined treatment with 131I-metaiodobenzylguanidine. Cancer 2002;97(5):1332–8. doi: 10.1002/cncr.11167.Garaventa A., Gambini C., Villavecchia G., Cataldo A., Bertolazzi L., Pizzitola M.R., de Bernardi B., Haupt R. Second malignancies in children with neuroblastoma after combined treatment with 131I-metaiodobenzylguanidine. Cancer 2002;97(5):1332–8. doi: 10.1002/cncr.11167.Huibregtse K.E., Kieuhoa T.V., Du Bois S.G., Fetzko S., Neuhaus J., Batra V., Maris J.M., Weiss B., Marachelian A., Yanik G.A., Matthay K.K. Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with 131I-metaiodobenzylguanidine. Eur J Cancer 2016;66:144–52. doi: 10.1016/j.ejca.2016.07.017.Huibregtse K.E., Kieuhoa T.V., Du Bois S.G., Fetzko S., Neuhaus J., Batra V., Maris J.M., Weiss B., Marachelian A., Yanik G.A., Matthay K.K. Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with 131I-metaiodobenzylguanidine. Eur J Cancer 2016;66:144–52. doi: 10.1016/j.ejca.2016.07.017.Moroz М., Machin D., Faldum A., Hero B., Iehara T., Mosseri V., Ladenstein R., de Bernardi B., Rubie H., Berthold F., Matthay K.K., Monclair T., Ambros P.F., Pearso A.D.J., Cohn S.L., London W.B. Changes over three decades in outcome and the prognostic infl uence of age-at-diagnosis in young patients with neuroblastoma: a report from the International Neuroblastoma Risk Group Project. Eur J Cancer 2011;47(4):561–71. doi:10.1016/j.ejca.2010.10.022.Moroz М., Machin D., Faldum A., Hero B., Iehara T., Mosseri V., Ladenstein R., de Bernardi B., Rubie H., Berthold F., Matthay K.K., Monclair T., Ambros P.F., Pearso A.D.J., Cohn S.L., London W.B. Changes over three decades in outcome and the prognostic infl uence of age-at-diagnosis in young patients with neuroblastoma: a report from the International Neuroblastoma Risk Group Project. Eur J Cancer 2011;47(4):561–71. doi:10.1016/j.ejca.2010.10.022.Sandoval С., Pui C.H., Bowman L.C., Heaton D., Raimondi S.C., Behm F.G., Head D.R. Secondary acute myeloid leukemia in children previously treated with alkylating agents, intercalating topoisomerase II inhibitors, and irradiation. J Clin Oncol1993;11(6):1039–45. doi: 10.1200/JCO.1993.11.6.1039.Sandoval С., Pui C.H., Bowman L.C., Heaton D., Raimondi S.C., Behm F.G., Head D.R. Secondary acute myeloid leukemia in children previously treated with alkylating agents, intercalating topoisomerase II inhibitors, and irradiation. J Clin Oncol1993;11(6):1039–45. doi: 10.1200/JCO.1993.11.6.1039.Kushner B.H., Cheung N.K., Kramer K., Heller G., Jhanwar S.C. Neuroblastoma and treatment-related myelodysplasia/leukemia: the Memorial Sloan-Kettering experience and a literature review. J Clin Oncol 2016;16(12):3880–9. doi: 10.1200/jco.1998.16.12.3880.Kushner B.H., Cheung N.K., Kramer K., Heller G., Jhanwar S.C. Neuroblastoma and treatment-related myelodysplasia/leukemia: the Memorial Sloan-Kettering experience and a literature review. J Clin Oncol 2016;16(12):3880–9. doi: 10.1200/jco.1998.16.12.3880.Hijiya N., Ness K.K., Ribeiro R.C., Hudson M.M. Acute leukemia as a secondary malignancy in children and adolescents: current fi ndings and issues. Cancer 2016;115(1):23–35. doi: 10.1002/cncr.23988.Hijiya N., Ness K.K., Ribeiro R.C., Hudson M.M. Acute leukemia as a secondary malignancy in children and adolescents: current fi ndings and issues. Cancer 2016;115(1):23–35. doi: 10.1002/cncr.23988.Barr E., Applebaum M. Genetic predisposition to neuroblastoma. Children 2018;5(9):119. doi:10.3390/children5090119.Barr E., Applebaum M. Genetic predisposition to neuroblastoma. Children 2018;5(9):119. doi:10.3390/children5090119.

The authors declare that there are no conflicts of interest present.